

## **CURRENT REPORT 2/2025**

**February 7, 2025**

### **Recommendation of Ryvu's project for funding by the Medical Research Agency**

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("Company") informs that on February 6th, 2025 it became aware of the placement of the Company's project titled "ADCraft – next-generation small molecule payloads for Antibody-Drug Conjugates in oncology" ("Project") on the ranked list of projects recommended for funding under the call for entrepreneurs to carry out research in the area of drug safety, innovative therapies and medicines of the future organized by the Medical Research Agency (in Polish: Agencja Badań Medycznych, "MRA"). The call was implemented as part of the National Recovery and Resilience Plan, Component D: Efficiency, accessibility and quality of the health care system, Investment D3.1.1: Comprehensive development of research in the field of medical and health sciences.

The aim of the Project is to develop methods for discovering and testing new generation of payloads for Antibody-Drug Conjugates (ADC) along with a portfolio of R&D activities focused on new therapeutic modalities used in oncology.

- the total net value of the Project is: PLN 13,172,227.85;
- recommended amount of the funding: PLN 9,879,170.99;
- the planned duration of the Project: 18 months.

In case the grant agreement is concluded and the Project is implemented, the granted funding may limit the use of the Company's own funds.

The Company will announce the conclusion of the relevant grant agreement with MRA, as well as other significant events related to the Project, in the form of current reports.

*Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.*

**Legal basis:** Article 17.1 of MAR

**Representatives of the Issuer:**

- Krzysztof Brzózka – Vice-President of the Management Board
- Kamil Sitarz – Member of the Management Board